Mateusz Opyrchal, MD, PhD
Assistant Professor of Medicine
Associate Director of the Early Phase Clinical Trials Program
Co-leader of the Adoptive Cellular Therapy Program
Co-leader of the Breast Disease Specific Research Group at Roswell Park Comprehensive Cancer Center, Buffalo, New York
Despite considerable advances and promising developments in recent years, metastatic breast cancer (mBC) continues to be a deadly disease. Although the first immune agonist was recently approved for patients with locally advanced or metastatic triple-negative breast cancer (mTNBC), the effectiveness of immunotherapy strategies in the treatment of mBC remains a work in progress.
... to read the full story